Latest Mannkind Corp (MNKD) Headlines 3 Stocks
Post# of 128
Posted On: 03/12/2014 11:50:41 PM
Latest Mannkind Corp (MNKD) Headlines
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 12, 3:25PM CDT
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Investor-Edge.com Pre-market Biotech Picks: Rexahn Pharma, Amgen, Galena Biopharma, and MannKind
PR Newswire - Tue Mar 11, 10:32AM CDT
On Monday, March 10, 2014, the NASDAQ Composite ended at 4,334.45, down 0.04%, the Dow Jones Industrial Average fell 0.21% to 16,418.68, and the S&P 500 closed at 1,877.17, down 0.05%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 689.78, up 0.39%, and has gained 4.92% in the last one month. Investor-Edge.com has initiated coverage on the following equities: Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Amgen Inc. (NASDAQ: AMGN), Galena Biopharma Inc. (NASDAQ: GALE), and MannKind Corporation (NASDAQ: MNKD). Free research on these four companies can be accessed at:
April 25th Options Now Available For MannKind (MNKD)
at The Street - Thu Mar 06, 10:06AM CST
Investors in MannKind Corp saw new options begin trading today, for the April 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNKD options chain for the new April 25th contracts and identified one put and...
Biotech Stock Mailbag Extra: MannKind's Afrezza Panel Setup
at The Street - Thu Mar 06, 9:14AM CST
A preview of the April 1 FDA advisory panel convened to review MannKind's inhaled insulin device.
Biotech Showdown: MannKind Corp. vs. Orexigen Therapeutics
George Budwell, The Motley Fool - Motley Fool - Tue Mar 04, 1:00PM CST
A drug approval for a developmental biotech can be a transformative event, especially when the drug in question has blockbuster potential. So, it's no wonder that risk-tolerant investors flock to drug stocks with pending New Drug Applications, or...
A Busy Calendar of March Biotech Events
at The Street - Mon Mar 03, 12:13PM CST
Drug approvals, FDA advisory panels and clinical trial results all on tap over the next 30 days.
Trend Report: 7 Insider And Hedge Fund Stock Picks To Consider
at The Street - Fri Feb 28, 4:35PM CST
Mary-Lynn Cesar, Kapitall: Insider and hedge fund stock picks don't always overlap, but when they do it makes for an [...]
Interesting MNKD Put And Call Options For April 19th
at The Street - Wed Feb 26, 11:07AM CST
Investors in MannKind Corp saw new options become available this week, for the April 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNKD options chain for the new April 19th contracts and identified one...
Cornerstone OnDemand CEO Adam Miller to Keynote Pacific Crest Emerging Tech SaaS Conference
Business Wire - Wed Feb 26, 7:01AM CST
Cornerstone OnDemand (NASDAQ:CSOD), a global leader in cloud-based talent management software solutions, today announced that the company's founder and CEO, Adam Miller, will deliver a keynote at the following investor conference:
5 Stocks Poised for Breakouts
at The Street - Fri Feb 21, 12:53PM CST
These stocks look ready to break out and trade higher from current levels.
5 Questions for MannKind
Brian Orelli, The Motley Fool - Motley Fool - Wed Feb 19, 6:47PM CST
MannKind was rather mum on its fourth quarter conference call Tuesday. That's somewhat understandable, with the upcoming Food and Drug Administration advisory committee meeting on April 1 reviewing Afrezza and hopefully a decision from the agency...
MannKind's Q4 Loss Wider than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 9:50AM CST
MannKind's loss of 16 cents per share in the fourth quarter of 2013 was wider than the Zacks Consensus Estimate of a loss of 14 cents.
MannKind Corporation to Present at Upcoming Conferences
GlobeNewswire - Wed Feb 19, 7:00AM CST
MannKind Corporation (Nasdaq:MNKD) focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at upcoming conferences.
The 5 Most Hated Biotechs: Myraid, Sarepta, Questcor, Ziopharm, and MannKind
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 18, 5:30PM CST
Looking at a company's short interest should be an integral part of an investor's due diligence. A high short interest isn't necessarily a reason shun a company, but understanding why investors are shorting the stock is important. The shorts may be...
3 Catalysts Biotech Investors Must Watch in 2014
Keith Speights, The Motley Fool - Motley Fool - Tue Feb 18, 5:30PM CST
Fortunes hang in the balance. In the next few months, some investors are going to make a lot of money. Unfortunately, some will also lose a bundle. Plenty of major decisions loom large for biotech stocks in 2014. Which should investors watch most...
MannKind's Q4 Loss Widens Modestly on Higher Stock Compensation Expenses
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 18, 4:26PM CST
Highly volatile biopharmaceutical company MannKind delivered its fourth-quarter earnings results before the opening bell this morning. Results point to higher costs as it readies for a PDUFA decision in April for the company's inhalable type 1...
Critical Alerts For SolarCity, Qualcomm, Bed Bath & Beyond, MannKind, and Groupon Released By InvestorsObserver
PR Newswire - Tue Feb 18, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for SCTY, QCOM, BBBY, MNKD, and GRPN.
MannKind Corporation Reports 2013 Fourth Quarter and Full Year Financial Results
GlobeNewswire - Tue Feb 18, 7:02AM CST
MannKind Corporation (Nasdaq:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2013.
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 12, 3:25PM CDT
I follow quite a lot of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Investor-Edge.com Pre-market Biotech Picks: Rexahn Pharma, Amgen, Galena Biopharma, and MannKind
PR Newswire - Tue Mar 11, 10:32AM CDT
On Monday, March 10, 2014, the NASDAQ Composite ended at 4,334.45, down 0.04%, the Dow Jones Industrial Average fell 0.21% to 16,418.68, and the S&P 500 closed at 1,877.17, down 0.05%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 689.78, up 0.39%, and has gained 4.92% in the last one month. Investor-Edge.com has initiated coverage on the following equities: Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Amgen Inc. (NASDAQ: AMGN), Galena Biopharma Inc. (NASDAQ: GALE), and MannKind Corporation (NASDAQ: MNKD). Free research on these four companies can be accessed at:
April 25th Options Now Available For MannKind (MNKD)
at The Street - Thu Mar 06, 10:06AM CST
Investors in MannKind Corp saw new options begin trading today, for the April 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNKD options chain for the new April 25th contracts and identified one put and...
Biotech Stock Mailbag Extra: MannKind's Afrezza Panel Setup
at The Street - Thu Mar 06, 9:14AM CST
A preview of the April 1 FDA advisory panel convened to review MannKind's inhaled insulin device.
Biotech Showdown: MannKind Corp. vs. Orexigen Therapeutics
George Budwell, The Motley Fool - Motley Fool - Tue Mar 04, 1:00PM CST
A drug approval for a developmental biotech can be a transformative event, especially when the drug in question has blockbuster potential. So, it's no wonder that risk-tolerant investors flock to drug stocks with pending New Drug Applications, or...
A Busy Calendar of March Biotech Events
at The Street - Mon Mar 03, 12:13PM CST
Drug approvals, FDA advisory panels and clinical trial results all on tap over the next 30 days.
Trend Report: 7 Insider And Hedge Fund Stock Picks To Consider
at The Street - Fri Feb 28, 4:35PM CST
Mary-Lynn Cesar, Kapitall: Insider and hedge fund stock picks don't always overlap, but when they do it makes for an [...]
Interesting MNKD Put And Call Options For April 19th
at The Street - Wed Feb 26, 11:07AM CST
Investors in MannKind Corp saw new options become available this week, for the April 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNKD options chain for the new April 19th contracts and identified one...
Cornerstone OnDemand CEO Adam Miller to Keynote Pacific Crest Emerging Tech SaaS Conference
Business Wire - Wed Feb 26, 7:01AM CST
Cornerstone OnDemand (NASDAQ:CSOD), a global leader in cloud-based talent management software solutions, today announced that the company's founder and CEO, Adam Miller, will deliver a keynote at the following investor conference:
5 Stocks Poised for Breakouts
at The Street - Fri Feb 21, 12:53PM CST
These stocks look ready to break out and trade higher from current levels.
5 Questions for MannKind
Brian Orelli, The Motley Fool - Motley Fool - Wed Feb 19, 6:47PM CST
MannKind was rather mum on its fourth quarter conference call Tuesday. That's somewhat understandable, with the upcoming Food and Drug Administration advisory committee meeting on April 1 reviewing Afrezza and hopefully a decision from the agency...
MannKind's Q4 Loss Wider than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 19, 9:50AM CST
MannKind's loss of 16 cents per share in the fourth quarter of 2013 was wider than the Zacks Consensus Estimate of a loss of 14 cents.
MannKind Corporation to Present at Upcoming Conferences
GlobeNewswire - Wed Feb 19, 7:00AM CST
MannKind Corporation (Nasdaq:MNKD) focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at upcoming conferences.
The 5 Most Hated Biotechs: Myraid, Sarepta, Questcor, Ziopharm, and MannKind
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 18, 5:30PM CST
Looking at a company's short interest should be an integral part of an investor's due diligence. A high short interest isn't necessarily a reason shun a company, but understanding why investors are shorting the stock is important. The shorts may be...
3 Catalysts Biotech Investors Must Watch in 2014
Keith Speights, The Motley Fool - Motley Fool - Tue Feb 18, 5:30PM CST
Fortunes hang in the balance. In the next few months, some investors are going to make a lot of money. Unfortunately, some will also lose a bundle. Plenty of major decisions loom large for biotech stocks in 2014. Which should investors watch most...
MannKind's Q4 Loss Widens Modestly on Higher Stock Compensation Expenses
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 18, 4:26PM CST
Highly volatile biopharmaceutical company MannKind delivered its fourth-quarter earnings results before the opening bell this morning. Results point to higher costs as it readies for a PDUFA decision in April for the company's inhalable type 1...
Critical Alerts For SolarCity, Qualcomm, Bed Bath & Beyond, MannKind, and Groupon Released By InvestorsObserver
PR Newswire - Tue Feb 18, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for SCTY, QCOM, BBBY, MNKD, and GRPN.
MannKind Corporation Reports 2013 Fourth Quarter and Full Year Financial Results
GlobeNewswire - Tue Feb 18, 7:02AM CST
MannKind Corporation (Nasdaq:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2013.
(0)
(0)